8-K: Trevi Therapeutics Announces 2023 Financial Results and Clinical Trial Updates

Trevi Therapeutics reported its fourth quarter and full-year 2023 financial results, along with updates on its ongoing clinical trials for Haduvio.

Summary

• Trevi Therapeutics announced its financial results for the fourth quarter and full year of 2023.
• The company is developing Haduvio for chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC).
• Trevi initiated Phase 2a and 2b trials for RCC and chronic cough in IPF respectively in the fourth quarter of 2023.
• The company also initiated the final part of the Human Abuse Potential (HAP) study.
• Topline data for the RCC trial and HAP study are expected in the second half of 2024.
• The sample size re-estimation (SSRE) for the chronic cough in IPF trial is also expected in the second half of 2024.
• Assuming no adjustments to the sample size, topline results for the chronic cough in IPF trial are expected in the first half of 2025.
• Trevi ended 2023 with $83.0 million in cash, cash equivalents, and marketable securities, with a cash runway into 2026.
• R&D expenses increased to $6.5 million in Q4 2023 from $4.3 million in Q4 2022, primarily due to increased clinical trial costs.
• The net loss for Q4 2023 was $7.8 million, compared to a net loss of $5.5 million in Q4 2022.
• For the full year 2023, R&D expenses were $23.7 million, compared to $19.8 million in 2022.
• The net loss for the full year 2023 was $29.1 million, compared to a net loss of $29.2 million in 2022.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the progress in clinical trials, strong cash position, and clear timelines for data readouts. However, the increased net loss and R&D expenses temper the overall sentiment.

Positives

• The company has a strong cash position of $83.0 million, providing a cash runway into 2026.
• Multiple clinical trials are progressing with patient enrollment.
• Topline data readouts are expected in the second half of 2024 for the RCC trial and HAP study.
• The company is addressing unmet needs in chronic cough with no approved treatments in the US.
• The company has initiated multiple clinical trials in the fourth quarter of 2023.

Negatives

• The company reported a net loss of $7.8 million for Q4 2023, which is higher than the $5.5 million loss in Q4 2022.
• R&D expenses have increased significantly due to the initiation of new clinical trials.
• The company is still in the clinical stage and has no approved products.

Risks

• The success of clinical trials is uncertain, and positive data may not predict results in later trials.
• Regulatory approvals for Haduvio are not guaranteed.
• The company's ability to fund future operations and clinical trials is subject to uncertainties.
• There are risks associated with estimating the company's cash runway and future expenses.
• The company is subject to risks and uncertainties related to its product development activities.

Future Outlook

The company anticipates a milestone year in 2024 with important data readouts in chronic cough, and expects to complete the sample size re-estimation for the chronic cough in IPF trial. The company expects to have a cash runway into 2026.

Management Comments

• Jennifer Good, President and CEO of Trevi Therapeutics, stated that she is proud of the progress made in 2023, with the initiation of clinical trials for RCC, chronic cough in IPF, and the final part of the HAP study.
• Management reaffirmed guidance to read out topline data in the second half of this year for the RCC trial and the HAP study.

Industry Context

The company is focused on developing treatments for chronic cough in IPF and RCC, areas with significant unmet needs and no approved therapies in the US. This positions Trevi to potentially capture a significant market share if Haduvio is approved.

Comparison to Industry Standards

• Trevi's focus on chronic cough in IPF and RCC is notable as there are currently no approved therapies for these conditions in the US, setting it apart from companies focused on more established markets.
• The company's cash runway into 2026 is a positive sign, as many clinical-stage biopharma companies face funding challenges.
• The increase in R&D expenses is typical for a company advancing multiple clinical trials, and is comparable to other companies in similar stages of development such as Galecto Biotech and Verona Pharma.
• The expected timelines for data readouts are consistent with industry standards for Phase 2 trials, and the company's transparency in communicating these timelines is a positive sign.

Stakeholder Impact

• Shareholders will be interested in the progress of clinical trials and the company's financial health.
• Employees will be impacted by the company's growth and development.
• Patients with chronic cough in IPF and RCC may benefit from the development of Haduvio.
• The company's suppliers and creditors will be impacted by its financial performance.

Next Steps

• The company will continue enrolling patients in the Phase 2a RIVER trial, Phase 2b CORAL trial, and the Human Abuse Potential (HAP) study.
• The company expects to conduct a sample size re-estimation (SSRE) for the CORAL trial in the second half of 2024.
• The company plans to participate in the 23rd Annual Needham Virtual Healthcare Conference in April 2024.
• The company plans to participate in the 3rd European Pulmonary Fibrosis Patient Summit 2024 in April 2024.
• The company expects topline data readouts for the RIVER trial and HAP study in the second half of 2024.
• The company expects topline results for the CORAL trial in the first half of 2025, assuming no adjustments to the sample size.

Key Dates

Keywords

Haduvio, chronic cough, idiopathic pulmonary fibrosis, refractory chronic cough, clinical trials, biopharmaceutical, nalbuphine ER, RIVER trial, CORAL trial, Human Abuse Potential study